The production of molybdenum-99 at the High Flux Reactor in Petten, the Netherlands, is unlikely to restart in February 2009 as had been planned, according to the facility’s operators, the Nuclear Research and Consultancy Group.
The production of molybdenum-99 at the High Flux Reactor in Petten, the Netherlands, is unlikely to restart in February 2009 as had been planned, according to the facility's operators, the Nuclear Research and Consultancy Group.
The HFR, one of two main sources of Mo-99 in Europe, has been out of action since mid-August when gas bubbles were found escaping into the reactor's cooling system. The cause of the leak was subsequently traced to corrosion between an external pipe and its concrete casing.
Engineers hope to seal the leak by inserting a sleeve into the pipe. But when a detailed repair plan was drawn up, it became evident that the process would take much longer than expected.
"The placement of a sleeve into the cooling system cannot be completed by mid-February as earlier anticipated but will take a few months longer," a spokesperson for the NRG told Diagnostic Imaging. "This extra time is necessary to complete the required qualification of materials and testing of the application procedures."
The NRG is now investigating whether the HFR could be restarted at an earlier date using unspecified "alternative measures."
Nuclear medicine services throughout Europe have already faced disruption to supplies of technetium-99m, the daughter nuclide of Mo-99, while the HFR has been offline. Another crunch in Tc-99m availability is expected in early January when imaging services resume their normal workloads after the holiday break.
Europe's other main producer of Mo-99, the BR-2 reactor in Mol, Belgium, closed for routine maintenance on Dec. 10 and will not restart until Jan. 13, 2009.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.